Modeling Parkinson's Disease in Rats: An Evaluation of 6-OHDA Lesions of the Nigrostriatal Pathway

2002/06/01 by Ronald Deumens, Arjan Blokland, Jos Prickaerts · 26 citations
Medicine · Neuroscience · #Parkinson's Disease Mechanisms and Treatments #Neurological disorders and treatments #Nerve injury and regeneration

paper · doi:10.1006/exnr.2002.7891

Cited by

• Challenges and Opportunities in Exploring Non‐Motor Symptoms in 6‐Hydroxydopamine Models of Parkinson's Disease: A Systematic Review
• Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. [europepmc]
• PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease. [europepmc]
• A highly reproducible rotenone model of Parkinson's disease. [europepmc]
• Glutamate receptors as therapeutic targets for Parkinson's disease. [europepmc]
• Automated quantitative gait analysis in animal models of movement disorders. [europepmc]
• Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition. [europepmc]
• Noradrenaline and Parkinson's disease. [europepmc]
• CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease. [europepmc]
• Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits. [europepmc]
• Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. [europepmc]
• Rodent models of Parkinson's disease: beyond the motor symptomatology. [europepmc]
• Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function. [europepmc]
• Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson's Disease: New Perspectives to a Long-Standing Model. [europepmc]
• The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders. [europepmc]
• Enhanced GABA Transmission Drives Bradykinesia Following Loss of Dopamine D2 Receptor Signaling. [europepmc]
• Molecular Hydrogen as a Neuroprotective Agent. [europepmc]
• Cell-specific pallidal intervention induces long-lasting motor recovery in dopamine-depleted mice. [europepmc]
• Early Life Stress, Depression And Parkinson's Disease: A New Approach. [europepmc]
• Insulin regulates astrocyte gliotransmission and modulates behavior. [europepmc]
• Widespread sex dimorphism in aging and age-related diseases. [europepmc]
• Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease. [europepmc]
• Pharmacological enhancement of TFEB-mediated autophagy alleviated neuronal death in oxidative stress-induced Parkinson's disease models. [europepmc]
• Exosomes derived from mesenchymal stem cells repair a Parkinson's disease model by inducing autophagy. [europepmc]
• Targeting thalamic circuits rescues motor and mood deficits in PD mice. [europepmc]
• Animal models of Parkinson's disease: bridging the gap between disease hallmarks and research questions. [europepmc]